Investors in AcelRx Pharmaceuticals Inc (ACRX - Get Report) saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new November 17th contracts and identified one put and one call contract of particular interest.The put contract at the $2.50 strike price has a current bid of 20 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $2.50, but will also collect the premium, putting the cost basis of the shares at $2.30 (before broker commissions). To an investor already interested in purchasing shares of ACRX, that could represent an attractive alternative to paying $3.27/share today. Because the $2.50 strike represents an approximate 24% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 78%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.00% return on the cash commitment, or 50.31% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for AcelRx Pharmaceuticals Inc, and highlighting in green where the $2.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $5.00 strike price has a current bid of 20 cents. If an investor was to purchase shares of ACRX stock at the current price level of $3.27/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $5.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 59.02% if the stock gets called away at the November 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACRX shares really soar, which is why looking at the trailing twelve month trading history for AcelRx Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACRX's trailing twelve month trading history, with the $5.00 strike highlighted in red: Considering the fact that the $5.00 strike represents an approximate 53% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 80%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.12% boost of extra return to the investor, or 38.46% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 135%, while the implied volatility in the call contract example is 147%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $3.27) to be 66%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
More from Stocks
Facebook Says It's Suspended 'Tens of Thousands' of Apps Following Investigation
Facebook says it has identified thousands of problematic apps and developers following an investigation in the wake of the Cambridge Analytica scandal last year.
Here's Why Apple's TV+ Could Be a Winner -- It's Playing the Long Game
Apple's aggressive $4.99 price point and one-year free trial mean that TV+ is virtually guaranteed to be in the streaming rotation for many cord-cutters in the short-term, and buys it time to iterate in the long term.
Tesla Board Must Face Trial to Defend Huge Elon Musk Pay Deal: Report
Judge rules Elon Musk held sway over the company's compensation committee in designing package that could balloon to $70 billion.
Apple Arcade Feels a Bit Like Streaming Services in Their Early Days
Apple's game-subscription service doesn't have many big-budget titles for now. But it's priced aggressively, has some quality titles and comes without ads or in-game purchases.